Show simple item record

dc.contributor.authorGoyal, L.
dc.contributor.authorMeric-Bernstam, F.
dc.contributor.authorHollebecque, A.
dc.contributor.authorMorizane, C.
dc.contributor.authorValle, Juan W
dc.contributor.authorKarasic, T. B.
dc.contributor.authorAbrams, T. A.
dc.contributor.authorKelley, R. K.
dc.contributor.authorCassier, P. A.
dc.contributor.authorFuruse, J.
dc.contributor.authorKlumpen, H. J.
dc.contributor.authorChang, H. M.
dc.contributor.authorChen, L. T.
dc.contributor.authorKomatsu, Y.
dc.contributor.authorMasuda, K.
dc.contributor.authorAhn, D. H.
dc.contributor.authorLi, K.
dc.contributor.authorBenhadji, K. A.
dc.contributor.authorWacheck, V.
dc.contributor.authorBridgewater, J. A.
dc.date.accessioned2022-11-30T10:21:25Z
dc.date.available2022-11-30T10:21:25Z
dc.date.issued2022en
dc.identifier.citationGoyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301177.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.4009en
dc.identifier.urihttp://hdl.handle.net/10541/625800
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4009en
dc.titleUpdated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangementsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMass General Cancer Center, Harvard Medical School, Boston, MAen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record